News Search Results
Feb 25, 2025, 10:28 ET Innovative Research to Advance Oligonucleotide Therapeutics now published in the Journal of Nucleic Acid Therapeutics
Rockland is a global biotechnology company manufacturing leading-edge tools for basic, applied, and clinical research for academic, biopharma, diagnostic, and agbio industries. We
More news about: Rockland Immunochemicals, Inc.
Feb 25, 2025, 09:05 ET Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment
company developing technologies to enable tissue, organoid or cell therapy without requiring life-long immunosuppression. Leveraging its proprietary biotechnology-derived Streptavidin-FasL fusion protein/biotin-PEG microgel (SA-FasL microgel) platform technology, iTOL-100, iTolerance is advancing a pipeline
More news about: NLS Pharmaceutics Ltd.; Kadimastem Ltd.
Feb 25, 2025, 09:00 ET IsomAb makes two key appointments; Dr Shi Yin Foo M.D. as Non-Executive Director and Dr Gary Burgess M.D. as Chief Medical Officer
England, Feb. 25, 2025 /PRNewswire/ -- IsomAb Ltd, a UK-based biotechnology company developing novel isoform-specific disease modifying antibody treatments, for peripheral arterial disease and other ischaemic conditions,
More news about: IsomAb Ltd
Feb 25, 2025, 09:00 ET BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA
available through the Company's website for a limited time following the conference. About BioMarinBioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The
More news about: BioMarin Pharmaceutical Inc.
Feb 25, 2025, 09:00 ET Debut Scores Breakthrough in Carmine Bioproduction and Unveils Plans to Launch the First-ever Molecular Replica of the Vibrant Red Pigment
tried to biomanufacture carmine over the years with no success due to the complexity and cost of inputs. It is only through the advancement of our biotechnology, Debut's proprietary Bio2Consumer™ platform, and our differentiated capabilities in biomanufacturing that this innovation has finally come to life."
More news about: Debut Biotechnology
Feb 25, 2025, 09:00 ET MycoWorks Unveils New Technology to Enhance the Performance of Its Flagship Biomaterial Reishi™ Now Available to Purchase Online
MycoWorks In 2013, artists Philip Ross and Sophia Wang formed MycoWorks, a biotechnology company dedicated to growing the future of materials. MycoWorks' patented Fine Mycelium™ platform engineers mycelium as it grows, crafting bio-materials
More news about: MycoWorks
Feb 25, 2025, 09:00 ET JLL Foundation accelerates climate mitigation by investing $4.75M in loans to 18 new climate-impacting startups
needs of each company. To highlight a few of the 2024 recipients, the Foundation's loans are helping: Mycocycle, a biotechnology startup using fungi to transform construction waste into low-carbon raw materials for the built environment, develop its next generation MYCOntainer™.Novoloop,
More news about: JLL-IR
Feb 25, 2025, 08:05 ET Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update
replay for 90 days after the call via the Rigel website. About RigelRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders
More news about: Rigel Pharmaceuticals, Inc.
Feb 25, 2025, 08:02 ET BridGene Biosciences Announces Strategic Collaboration with Takeda to Discover Small Molecule Drugs for Immunology and Neurology Targets
undruggable, aligning with our core strategy in small molecule drug discovery." About BridGene BiosciencesBridGene is a biotechnology company focused on discovering and developing innovative small molecules that drug traditionally undruggable targets, providing new paths to treat
More news about: BridGene Biosciences
Feb 25, 2025, 08:00 ET Spyre Therapeutics to Participate in Upcoming March Investor Conferences
Feb. 25, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory
More news about: Spyre Therapeutics, Inc.
Feb 25, 2025, 08:00 ET Panome Bio Welcomes Jean-Pierre Wery to Its Board of Directors as it Prepares for Growth in 2025
Panome Bio, a leading discovery services company, announced the addition of accomplished biotechnology leader Jean-Pierre Wery to its Board of Directors. Dr. Wery, a seasoned executive with a proven track record in scaling
More news about: Panome Bio
Feb 25, 2025, 08:00 ET CARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China
Xinchuang") to jointly invest in UCARsgen Biotech Limited ("UCARsgen"), a China-based new drug discovery biotechnology company focused on allogeneic CAR-T cell therapies for the treatment of hematologic malignancies.
More news about: CARsgen Therapeutics
Feb 25, 2025, 08:00 ET Inceptor Bio Announces First Patient Dosed in Clinical Trial of IB-T101 for Clear Cell Renal Cell Carcinoma (ccRCC) and $21M Series A2 Financing
N.C., Feb. 25, 2025 /PRNewswire/ -- Inceptor Bio, a clinical-stage biotechnology company pioneering next-generation cell therapies, today announced that the first patient has been dosed in the clinical trial of IB-T101, the company's
More news about: Inceptor Bio
Feb 25, 2025, 08:00 ET Ottimo Pharma Strengthens Leadership Team with Senior Appointments
expected to enter clinical trials following an IND filing in late 2025. About Ottimo PharmaOttimo Pharma is a private biotechnology company, co-founded by Medicxi and Jonny Finlay, that emerged from stealth in October
More news about: Ottimo Pharma
Feb 25, 2025, 08:00 ET Vevo Therapeutics Open Sources Tahoe-100M, the World's Largest Single-Cell Dataset, as the Inaugural Contribution to Arc Institute's New Virtual Cell Atlas
curiosity-driven research agendas and fosters deep interdisciplinary collaboration. About Vevo Therapeutics Vevo Therapeutics is a biotechnology company using its in vivo drug discovery platform and next-generation AI models to uncover better drugs for more patients. The company's Mosaic
More news about: Vevo Therapeutics
Feb 25, 2025, 07:30 ET Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' "America Reports"
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its breast cancer vaccine was featured on Fox News' "America Reports."
More news about: Anixa Biosciences, Inc.
Feb 25, 2025, 07:00 ET Setting a New Standard for Intelligent Factories: Angel Yeast Drives Eco-Collaboration and Human-Machine Coexistence in Smart Production
bio-products. Hubei Maiggic Technology positions itself in nutraceutical ingredients and personal care functional materials, with Hubei PHAngel Biotechnology dedicated to PHA bio-based biodegradable materials development. The symbiotic effect of the industrial chain is particularly pronounced.
More news about: Angel Yeast
Feb 25, 2025, 07:00 ET Setting a New Standard for Intelligent Factories: Angel Yeast Drives Eco-Collaboration and Human-Machine Coexistence in Smart Production
bio-products. Hubei Maiggic Technology positions itself in nutraceutical ingredients and personal care functional materials, with Hubei PHAngel Biotechnology dedicated to PHA bio-based biodegradable materials development. The symbiotic effect of the industrial chain is particularly pronounced.
More news about: Angel Yeast
Feb 25, 2025, 07:00 ET Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy
initiatives around Vaccine Efficacy Testing." About Virax Biolabs Group Limited Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based
More news about: Virax Biolabs
Feb 25, 2025, 07:00 ET Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
25, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company specializing in precision local drug delivery, today announced additional positive clinical data from its ongoing RESOLVE Phase 1b/2a
More news about: Eupraxia Pharmaceuticals Inc.
Feb 25, 2025, 06:45 ET Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Feb 25, 2025, 05:45 ET ICLR LAWSUIT ALERT: Levi & Korsinsky Notifies ICON Public Limited Company Investors of a Class Action Lawsuit and Upcoming Deadline
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Levi & Korsinsky, LLP
Feb 25, 2025, 03:00 ET VIVICI SECURES €32.5 MILLION IN SERIES A FUNDING
fermentation – the method used by Vivici to create dairy protein - combines the process of traditional fermentation with the latest advances in biotechnology, producing proteins without the need for animals. The technology promises to sustainably meet the protein needs of the world's growing population,
More news about: Vivici B.V.
Feb 25, 2025, 03:00 ET Julius Clinical Strengthens its European Capabilities by Expanding Operations in Poland
combines scientific leadership, operational excellence, and a global network of research sites to deliver tailored solutions for pharmaceutical, biotechnology, and academic partners. For more information, visit
More news about: Julius Clinical Research
Feb 24, 2025, 18:30 ET Kessler Topaz Meltzer & Check, LLP Encourages ICON Public Limited Company Investors with Losses to Contact the Firm
insufficient to shield the company from the adverse effects of a significant market downturn; (3) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Kessler Topaz Meltzer & Check, LLP